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Foreword – Will HPV Vaccines
Prevent Cervical Cancers Among Poor
Women of Color?: Global Health
Policy at the Intersection of Human
Rights and Intellectual Property Law
Kevin Outterson†

Cervical cancer is a disease of social inequality.1 Women with access to
effective screening and treatment rarely die from cervical cancer. The burden
of cervical cancer mortality falls most heavily among the poorer women of the
world.2 Cervical cancer starkly illustrates global inequality across race, sex
and class. Cervical cancer disproportionately kills poor women of color.
The HPV vaccine is a triumph of science. Current formulations may well
prevent infection from the HPV subtypes responsible for approximately 70
percent of cervical cancers, and multi-valiant vaccines are under development
to expand the scope of coverage.3 Nobel Prizes are won for such path breaking
science.
And yet, the HPV vaccine is the most expensive vaccine in human history,
priced at approximately $360 wholesale for the currently recommended
regime of three doses.4 Through an accident of patent litigation, we have two
brand name manufacturers (Merck and GlaxoSmithKline), but no apparent
competition on price.
More troubling, the vaccine is being initially sold to the very people who
need it least: the well-insured daughters of the middle class in the US and
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other wealthy OECD countries. Even within the US, the vaccine is going to
those with social and financial capital to access vaccination programs, the very
women most likely to also have access to effective screening and treatment.5
In other words, the vaccine is prioritized to the women who need it least. The
women most likely to die of cervical cancer in the US are poor women of color,
and they may be the least vaccinated group. This inequality reflects the social
realities on the ground in the U.S.
These inequalities are magnified when we look at cervical cancer globally.
In the wealthiest 34 countries of the world, less than 19,000 women died of
cervical cancer last year, compared to more than 240,000 in the rest of the
world.6 The primary commercial markets for the vaccine account for only
seven percent of the mortality.7 For the foreseeable future, the lion’s share of
HPV vaccine production will go to the countries that need it least, and within
those countries to the women who need it least. All of this activity is
protected by global intellectual property rules under the WTO TRIPS
Agreement.
One surprising aspect of HPV is that most of the controversy focuses on
claims about the sexual practices of adolescents8 rather than these glaring
global inequalities. A vaccine that prevents cancers that kill poor women of
color is now available, but the primary recipients will be wealthy white
women. This should be a human rights issue of the first rank.
The Symposium that follows begins these conversations. Key researchers,
public health experts, global health activists, and representatives of Merck
came to Boston to discuss these issues thoroughly. Dr. Jim Yong Kim of the
Harvard Medical School gave the keynote lecture, focusing on the global
inequalities in cervical cancer. He was introduced by Professor George Annas,
a distinguished human rights scholar at the Boston University School of
Public Health and School of Law. Dr. Mark Feinberg, a vice president in
Merck’s global vaccine unit, gave lunch keynote speech. Feinberg offered his
perspectives, both in his speech and in many questions raised during the
discussion periods. We are especially indebted to the Harvard Interfaculty
Initiative on Medications and Society, which co-sponsored the Symposium
with the American Society of Law, Medicine & Ethics; the Health Law
Program at Boston University School of Law; and the American Journal of
Law & Medicine. Jennifer Dixon did a superb job as Symposium Editor.
The Symposium begins where many of the key inventions occur:
university research labs. Sara E. Crager, Ethan Guillen and Matt Price discuss
the intellectual history of the HPV vaccines, deeply rooted in university and
other publicly funded research.9 Universities celebrate a unique social
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mission, not limited to strict corporate fiduciary duties to shareholders.
Universities are also tasked with the creation of public goods, including
knowledge for the benefit of humanity. In a nuanced article, they explore how
university technology transfer offices could support access to university
research for the developing world, without undermining the commercial and
research enterprise. They draw upon their experience as leaders in a studentled organization, Universities Allied for Essential Medicines, as well as their
work in medicine. Recognizing that large molecule vaccines are quite
different from small molecule generics, Crager, Guillen and Price discuss the
biology of HPV vaccine production in significant detail, avoiding
overgeneralizations about these technical and difficult processes.
A second article follows this university-lab theme, but this time from
lawyers. Beirne Roose-Snyder and Megan K. Doyle propose a Global Health
Licensing Program to maximize equitable access to innovation from university
labs.10 They build upon the work of April Effort and Ashley Stevens of Boston
University’s technology transfer office,11 articulating intellectual property
licensing provisions that might find commercial acceptance while supporting
global health. Their approach is pragmatic and flexible, looking for licensing
language that meets the needs of all stakeholders, including global health.
This article includes useful examples of language for the global licensing
toolbox.
Another important institution in global vaccine markets is the Pan
American Health Organization (PAHO). Jon Kim Andrus and his colleagues
at PAHO and the Sabin Vaccine Institute discuss PAHO’s important role in
bridging the gap from the factory to the low-income patient.12 Acting as a
financial and management intermediary for vaccines in the Western
Hemisphere, PAHO operates the Revolving Fund for Vaccine Procurement,
which facilitates procurement on behalf of many PAHO member countries.
Mexico13 has negotiated a HPV vaccine price of $34 for the three-dose course.
The PAHO Revolving Fund price is likely to be lower than that price,14
partially because PAHO insists on receiving the “best price” globally for
Revolving Fund purchases, which would necessitate a price of $34 or less.
Merck is unhappy with the PAHO “best price” rule, arguing that in some cases
the PAHO Revolving Fund shouldn’t receive the absolute best global price, as
its countries, on average, are not the poorest in the world. This position has
merit, since price discrimination is generally welfare enhancing and this rule
blocks price discrimination in favor of populations poorer than those served
10
Beirne Roose-Snyder & Megan K. Doyle, Global Health Licensing Program: A New
Model For Humanitarian Licensing at the University Level, 35 Am. J. L. & Med. 281 (2009).
11
April E. Effort & Ashley J. Stevens, Using Academic License Agreements to Promote
Global Social Responsibility, 43 Les Nouvelles: J. Licensing Executives Soc’y 85 (2008).
Ashley Stevens discussed this paper at the Symposium.
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Jon Kim Andrus et al., New Vaccines for Developing Countries: Will it be Feast of
Famine?, 35 Am. J. L. & Med. 311 (2009).
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Mexico is not a Revolving Fund recipient country.
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The cost effective price in Brazil has been estimated at approximately $25. Jan M.
Agosti & Sue J. Goldie, Introducing HPV Vaccine in Developing Countries – Key Challenges
and Issues, 356 New Eng. J. Med. 1908, 1909-10 (2007). In poorer countries with per capital
incomes around $1000, the cost effective price is in the range of $3 to $6. Helen Saxenian,
Program for Appropriate Technology Health (PATH), HPV Vaccine Adoption in
Developing Countries: Cost and Financing Issues 8-11 (2007).
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by the PAHO Revolving Fund.15 Even if the PAHO price is less than $34, the
HPV vaccine is very expensive compared to the current childhood vaccine
package (DPT-HiB-HB, BCG, MMR, and Polio), which is priced at $24 in
PAHO. This article provides important information on how HPV vaccines
will require financing and management in order to roll out effectively across
the Americas.
Our fourth article departs from the voluntary world of procurement and
licensing contracts and suggests that the credible threat of compulsory
licensing is an important component to achieving affordable HPV vaccines.16
Peter Maybarduk and Sarah Rimmington, attorneys with Essential Action,
discuss the practical barriers to compulsory licensing of HPV vaccines,
including identifying relevant patents in the absence of a global Orange Book,
attracting knowledgeable generic producers, overcoming barriers to export
posed by Article 31(f) of TRIPS, achieving registration as a bio-similar, and
paying adequate remunerations under Article 31(h). Their work here is
practical and straightforward legal analysis on a controversial topic, leaving
the politics of compulsory licenses for another day.
Abigail English, Carol A. Ford, and John S. Santelli’s article, Clinical
Preventive Services for Adolescents: Position Paper of the Society for Adolescent
Medicine, moves away from intellectual property law to an explicit concern
with human rights.17 They focus on financial access to HPV vaccines and also
with parental consent rules that may hinder population acceptance of the
vaccine. They ground their concerns in international human rights law,
particularly the United Nations Convention on the Rights of the Child.18 In
the U.S., relevant financing mechanisms to improve access include Medicaid,
SCHIP, private insurance, and the Vaccines for Children and “Section 317”
programs. Some of these programs terminate coverage at age 19, which is too
young for some women eligible for the HPV and other adolescent vaccines.19
The law must adapt to new health care modalities in order to protect human
rights appropriately.
Joanna N. Erdman further explores the human rights context, and finds
cervical cancer to be an especially compelling case, due to the social
inequalities endemic in its mortality patterns.20 For Erdman, something more
compelling than mere health inequality is present here:

15
See Kevin Outterson, Pharmaceutical Arbitrage: Balancing Access and Innovation
in International Prescription Drug Markets, 5 Yale J. Health Pol’y L. & Ethics 193, 203-05
(2005).
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Peter Maybarduk & Sarah Rimmington, Compulsory Licenses: A Tool to Improve
Global Access to the HPV Vaccine?, 35 Am. J. L. & Med. 323 (2009).
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Abigail English et al., Clinical Preventive Services for Adolescents: Position Paper of
the Society for Adolescent Medicine, 35 Am. J. L. & Med. 351 (2009).
18
U.N. Convention on the Rights of the Child, G.A. Res. 44/25, U.N. Doc.
A/RES/44/25 (Nov. 20, 1989), at Art. 24. The United States is not a party to this Convention.
19
English, supra note 17.
20
Erdman, supra note 1.
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Central to health equity is thus not the association of health
distribution with the social hierarchy, nor the fact of existing
prevention measures, but the capacity of government to change
the social hierarchy or to modify its effects on the distribution of
health risks and outcomes. There are important reasons to
empirically locate the cause of social health disparities in
government action, among them, providing an explanation why
social health disparities are unjust, the normative dimension of
health equity.21
Erdman concludes that cervical cancer disparities violate the
International Covenant on Economic, Social and Cultural Rights and the
Convention on the Elimination of All Forms of Discrimination against
Women.22 She is careful to not claim a human right to the HPV vaccine, but
calls for effective prevention and treatment of cervical cancer, especially for
the poorest women most burdened. Prevention and treatment can come in
many effective forms, including cervical screening and the HPV vaccine. But
if weaknesses in infrastructure retard screening, Erdman argues, the moral
and legal obligation increases for dissemination of the vaccine.
Leaving aside the manufacturing, financing and legal issues, Gregory D.
Zimet asks how the vaccines should be delivered for maximum health impact.
He explores both school-based and clinic-based programs, concluding that the
Domestic decisions can
former works better for HPV vaccination.23
sometimes have unintended consequences for global public health, as in the
case of the US FDA withdrawal of the rotavirus vaccine and thimerasol
vaccine preservatives, which he claims inappropriately dampened demand in
developing countries. He also highlights some of the work by PATH to
streamline HPV delivery and study related cultural issues in developing
countries.
PATH’s important work is center-stage in Vivien Davis Tsu’s article. She
finds reasons enough to be “cautiously optimistic” that HPV vaccines will
reach the women in greatest need, reducing health inequities rather than
exacerbating them.24 Tsu deploys cost-effectiveness analysis to identify the
public health priorities for HPV. Vaccination of boys and older girls is set
aside for the time being to focus on the group promising the greatest benefit:
pre-adolescent girls before sexual debut.25 While not discussed in her article
explicitly, it seems clear that within that group the public health focus should
be on those women least likely to have access to good screening and treatment
for cervical cancer, namely, women in poverty in developing countries.
Indeed, the balance of her article discusses cultural and other barriers to
adoption in developing country and other resource-limited settings. Tsu also
touches on financing, a persistent issue in this Symposium, noting that Merck
and GlaxoSmithKline have publicly committed to tiered (differential) pricing,
21

Erdman, supra note 1, at 380.
Id. at 381.
23
Gregory D. Zimet, Potential Barriers to HPV Immunization: From Public Health to
Personal Choice, 35 Am. J. L. & Med. 389, 393-98 (2009).
24
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Low-Income Countries, 35 Am. J. L. & Med. 401, 409 (2009).
25
Id. at 404-05.
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commensurate to the income level of the target countries.26 A senior
representative from Merck reiterated this commitment at the Symposium,
vowing to sell Gardasil “at cost” for the poorest countries, presumably the
GAVI-eligible countries. This pledge, if fulfilled, will go a long way to
achieving the ultimate objectives of both Universities Allied for Essential
Medicines and advocates for compulsory licensing, albeit through different
means. Financing HPV vaccine acquisition remains a key hurdle for cervical
cancer prevention, both in GAVI-eligible countries and in middle-income
countries not eligible for international subsidies.
In our final article, Sean McElligott explores two other licensing options
for HPV vaccines, the Generic Opportunity (GO) License,27 and his own
proposal to encourage voluntary contract production by developing world
vaccine manufacturers.28 He suggests that vaccine firms will flee the market if
they are inadequately compensated under the GO License, but the GO License
is entirely voluntary and does not affect patent-based firm revenues in the
wealthy countries of the world, representing more than 90 percent of the HPV
vaccine market in dollar terms.29 Voluntary contract production is a good way
to expand and diversify manufacturing capacity, but it does not necessarily
lead to marginal cost pricing in developing countries. McElligott’s article
discusses complex issues of pricing and intellectual property licensing with an
appealing level of sophistication. These issues are multifaceted, and deserve
thoughtful treatment, as he had given us.
In conclusion, I should note that while this Symposium focuses on HPV
vaccines, many of these issues find resonance with any patented medicine or
device that could have significant global health impact in across high-,
medium- and low-income populations. Human rights, intellectual property,
and global health intersect in this important field.

26

Id. at 408.
Outterson & Kesselheim, supra note 5, at 135.
28
Sean McElligott, Addressing Supply Side Barriers To Introduction of New Vaccines
To the Developing World, 35 Am. J. L. & Med. 415 (2009).
27

https://doi.org/10.1177/009885880903500201 Published online by Cambridge University Press

